Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria

S Dini; SG Zaloumis; DJ Price; N Gobeau; A Kümmel; M Cherkaoui; JJ Moehrle; JS McCarthy; JA Simpson

Journal article

Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria

S Dini, SG Zaloumis, DJ Price, N Gobeau, A Kümmel, M Cherkaoui, JJ Moehrle, JS McCarthy, JA Simpson

Journal of Antimicrobial Chemotherapy | OXFORD UNIV PRESS | Published : 2021

DOI: 10.1093/jac/dkab181

Abstract

Background: The efficacy of artemisinin-based combination therapies (ACTs), the first-line treatments for uncomplicated falciparum malaria, has been declining in malaria-endemic countries due to the emergence of malaria parasites resistant to these compounds. Novel alternative therapies are needed urgently to prevent the likely surge in morbidity and mortality due to failing ACTs. Objectives: This study investigates the efficacy of the combination of two novel drugs, OZ439 and DSM265, using a biologically informed within-host mathematical model. Methods: A within-host model was developed, which accounts for the differential killing of these compounds against different stages of the parasite'..

View full abstract

University of Melbourne Researchers

Saber Dini Author

Sophie Zaloumis Author

David Price Author

James McCarthy Author

Related Projects (2)

CENTRE FOR RESEARCH EXCELLENCE IN MALARIA ELIMINATION

The CRE will work to accelerate progress towards malaria elimination in our region, through Surveillance, to develop better ways to monitor ..

Tropical diseases: Translating discoveries into better health

Major progress being made in control of many infectious diseases occurring in tropical areas, including malaria worms and the bacteria that ..

Grants

Awarded by Bill and Melinda Gates Foundation

Funding Acknowledgements

This work was supported in part by the Australian Centre for Research Excellence in Malaria Elimination, funded by the NHMRC (1134989). J.A.S. is funded by an Australian National Health and Medical Research Council of Australia (NHMRC) Investigator Grant (1196068). J.S.M. is funded by an NHMRC Program Grant (1132975) and Practitioner Fellowship (1041802). The clinical trials (NCT02389348, NCT02573857, ACTRN12613000522718, ACTRN12613000527763 and ACTRN12612000814875) from which the data were derived were supported by the Medicines for Malaria Venture (MMV) and funded by the Wellcome Trust (grant reference number: 095909/Z/11/Z), a grant by the Global Health Innovation and Technology Fund (GHIT) (grant no. G2014-108) and by funding from the Bill & Melinda Gates Foundation.